Search

Basophils are important in allergic diseases such as asthma because they produce a variety of inflammatory mediators. Activation of these cells with IgE and N-formyl-methionyl-leucyl-phenylalanine results in a variety of responses, including increased surface expression of CD203c and CD11b and release of histamine. Although considerable information is available on the effects of eicosanoids on neutrophils, eosinophils, and monocytes, less is known about their effects on basophils. In the present study, we examined the effects of various eicosanoids on the above basophil responses. Of the naturally occurring eicosanoids tested, prostaglandin D(2) (PGD(2); EC(50), 10 nM) was by far the most potent activator of CD203c expression, with other prostanoids having little effect. This response was mediated by the DP(2) receptor/chemoattractant receptor-homologous molecule expressed on Th2 cells because it was shared by the selective agonist 15R-methyl-PGD(2) (EC(50), 3 nM). The 5-lipoxygenase products leuko-triene B(4) and 5-oxo-6,8,11,14-eicosatetraenoic acid also stimulated CD203c expression but to a lesser extent than PGD(2), whereas leukotriene D(4) was inactive. Neither PGD(2) nor 5-oxo-6,8,11,14-eicosatetraenoic acid stimulated histamine release or CD63 expression on basophils. Both PGE(2) and the DP(1) receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] strongly inhibited DP(2) receptor-mediated CD203c expression. The DP(1) receptor antagonist BWA868C [3-[(2-cyclohexyl-2-hydroxyethyl)amino]-2,5-dioxo-1-(phenylmethyl)-4-imidazolidine-heptanoic acid] enhanced PGD(2)-induced CD203c expression, suggesting that interaction of PGD(2) with DP(1) receptors can limit activation of basophils by this prostaglandin. In conclusion, PGD(2) is the most potent inducer of basophil CD203c expression among eicosanoids and may be a key mediator in asthma and other allergic diseases. The balance between DP(1) and DP(2) receptors may be important in determining the magnitude of basophil responses to this prostaglandin.

Abstract The diagnosis of immediate allergy is mainly based upon an evocative clinical history, positive skin tests (gold standard) and, if available, detection of specific IgE. In some complicated cases, functional in vitro tests are necessary. The general concept of those tests is to mimic in vitro the contact between allergens and circulating basophils. The first approach to basophil functional responses was the histamine release test but this has remained controversial due to insufficient sensitivity and specificity. During recent years an increasing number of studies have demonstrated that flow cytometry is a reliable tool for monitoring basophil activation upon allergen challenge by detecting surface expression of degranulation/activation markers (CD63 or CD203c). This article reviews the recent improvements to the basophil activation test made possible by flow cytometry, focusing on the use of anti-CRTH2/DP2 antibodies for basophil recognition. On the basis of a new triple staining protocol, the basophil activation test has become a standardized tool for in vitro diagnosis of immediate allergy. It is also suitable for pharmacological studies on non-purified human basophils. Multicenter studies are now required for its clinical assessment in large patient populations and to define the cut-off values for clinical decision-making.

The diagnosis of immediate allergy is mainly based upon an evocative clinical history, positive skin tests (gold standard) and, if available, detection of specific IgE. In some complicated cases, functional in vitro tests are necessary. The general concept of those tests is to mimic in vitro the contact between allergens and circulating basophils. The first approach to basophil functional responses was the histamine release test but this has remained controversial due to insufficient sensitivity and specificity. During recent years an increasing number of studies have demonstrated that flow cytometry is a reliable tool for monitoring basophil activation upon allergen challenge by detecting surface expression of degranulation/activation markers (CD63 or CD203c). This article reviews the recent improvements to the basophil activation test made possible by flow cytometry, focusing on the use of anti-CRTH2/DP2 antibodies for basophil recognition. On the basis of a new triple staining protocol, the basophil activation test has become a standardized tool for in vitro diagnosis of immediate allergy. It is also suitable for pharmacological studies on non-purified human basophils. Multicenter studies are now required for its clinical assessment in large patient populations and to define the cut-off values for clinical decision-making. [ABSTRACT FROM AUTHOR]